2,4-diarylpyrrolidine-3-carboxylic acids - Potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722

Journal of Medicinal Chemistry

Volumn 39, Issue 5, 1996, Pages 1039-1048

  Winn, Martin ^a   Von Geldern, Thomas W ^a   Opgenorth, Terry J ^a   Jae, Hwan Soo ^a   Tasker, Andrew S ^a   Boyd, Steven A ^a   Kester, Jeffrey A ^a   Mantei, Robert A ^a   Bal, Radhika ^a   Sorensen, Bryan K ^a   Wu Wong, Jinshyun R ^a   Chiou, William J ^a   Dixon, Douglas B ^a   Novosad, Eugene I ^a   Hernandez, Lisa ^a   Marsh, Kennan C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 PYRROLIDINECARBOXYLIC ACID DERIVATIVE; 4 (1,3 BENZODIOXOL 5 YL) 1 [[(DIBUTYLAMINO)CARBONYL]METHYL] 2 (4 METHOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; L 749329; PHOSPHATIDYLINOSITIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING COMPETITION; CEREBELLUM; CHO CELL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPOPHYSIS CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHOINOSITIDE METABOLISM; RABBIT; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; SWINE; THORACIC AORTA; VASOCONSTRICTION;

ANIMALS; AORTA; BIOLOGICAL AVAILABILITY; ENDOTHELINS; HYDROLYSIS; MALE; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOLS; PYRROLIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTION;

EID: 0029945669     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9505369     Document Type: Article

References (36)

1. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Goto, K.; Masaki, T. A. Novel Potent Vasoconstrictor Peptide Produced by Vascular Endothelin Cells. Nature 1988, 332, 311-415.
2. Opgenorth, T. J. Endothelin Receptor Antagonists. In Advances in Pharmacology; Academic Press: Orlando, FL, 1995; Vol. 33, pp 1-65.
3. Warner, T. Endothelin Receptor Antagonism. Cardiovasc. Drug Rev. 1994, 12, 105-122.
4. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The Human Endothelin Family: Three Structurally and Pharmacologically Distinct Isopeptides Predicted By Three Separate Genes. Proc. Natl. Acad. Sci. 1989, 86, 2863-2867.
5. Warner, T. D.; Mitchell, J. A.; De Nucci, G.; Vane, J. R. Endothelin-1 and Endothelin-3 Release EDRF From Isolated Perfused Arterial Vessels of the Rat and Rabbit. J. Cardiovasc. Pharmacol. 1989, 13 (suppl 5), S85-S88.
6. Hosoda, K.; Nakoa, K.; Arai, H.; Suga, S.; Ogawa, Y.; Mukoyama, M.;Shirakami, G.; Saito, Y.; Nakanishi, S.; Imura, H. Cloning and Expression of Human Endothelin-1 Receptor cDNA. FEBS Lett. 1991, 287, 23-26.
7. Ogwa, Y.; Nakao, K.; Arai, H.; Nagakawa, O.; Hosoda, K.; Suga, S.; Nakanishi, S.; Imura, H. Molecular Cloning of a Nonisopeptide Selective Human Endothelin Receptor. Biochem. Biophys. Res. Commun. 1992, 178, 248-255.
8. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T.; Nishikibe, M.; Yano, M. Biochemical and Pharmacological Profile of a Potent and Selective Endothelin B-Receptor Antagonist, BQ-788 Proc. Natl. Acad. Sci. USA 1994, 91, 4892-4896.
9. Moreland, S.; McMullen, D.; Abboa-Offei, B.; Seymour, A. Evidence for a Differential Location of Vasoconstrictor Endothelin Receptors in the Vasculature. Br. J. Pharmacol. 1994, 112, 704-708.
10. A Receptor Activation. Am. J Physiol. 1993, 264, R222-R226.
11. Seo, B.; Oemar, B.; Siebenmann, R.; von Segesser, L.; Luscher, T. Both ETA and ETB Receptors Mediate Contraction to Endothelin-1 in Human Blood Vessels. Circulation 1994, 89, 1203-1208.
12. Benigni, A.; Zoja, C.; Corna, D.; Orisio, S.; Longaretti, L.; Bertani, T.; Remuzzi, G. A Specific Endothelin Subtype A Receptor Antagonist Protects Against Injury in Renal Disease Progression. Kidney Int. 1994, 44, 440-444.
13. Miyugachi, T.; Yorikane, R.; Sakai, S.; Sakurai, T.; Okada, M.; Nishikibe, M.; Yano, M.; Yamaguchi, I.; Sugishita, Y.; Goto, K. Contribution of Endogenous Endothelin-1 to the Progression of Cardiopulmonary Alterations in Rats with Monocrotaline-induced Pulmonary Hypertension. Circulation Res. 1993, 73, 887-897.
14. A-receptor Antagonist, Attenuates Hypoxic Pulmonary Hypertension in Rats. Am. J. Physiol. 1994, 226, H1327-H1331.
15. A Receptor Antagonist Reduces Myocardial Infarction Induced by Coronary Artery Occlusion and Reperfusion in the Rat. Pharmacology 1994, 49, 319-324.
16. A Receptor Antagonist, Prevents the Early Cerebral Vasospasm Following Subarachnoid Hemorrhage after Intracisternal but not Intravenous Injection. Life Sci. 1993, 52, 825-834.
17. Clozel, M.; Breu, V.; Burri, K.; Cassal, J.; Fischli, W.; Gray, G.; Hirth, G ; Loffler, B.; Muller, M.; Neidhart, W.; Ramuz, H. Pathophysiological Role of Endothelin Revealed by the First Orally Active Endothelin Receptor Antagonist. Nature 1993, 365, 759-761.
18. A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide. J. Med. Chem. 1994, 37, 329-331.
19. A Receptor Antagonist, J. Pharmacol. Exp. Ther. 1995, 272, 1124-1134.
20. Elliot, J. D.; Lago, M. A.; Cousins, R. D.; Gao, A.; Leber, J. D.; Erhard, K. F.; Narabi, P.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Bean, J. W.; DeBrosse, C. W.; Eggleston, D. S.; Brooks, D. P.; Feuerstein, G.; Ruffolo, R. R.; Weinstock, J.; Gleason, J. G.; Peishoff, C. E.; Ohlstein, E. H. 1,3-Diarylindan-2-carboxylic Acids, Potent and Selective Non-Peptide Endothelin Receptor Antagonists. J. Med. Chem. 1994, 37, 1553-1557.
21. Walsh, T. F.; Fitch, K. J.; Chakravarty, P. K.; Williams, D. L.; Murphy, K. A.; Nolan, N. A.; O'Brien, J. A.; Lis, E. V.; Pettibone, D. J.; Kivlighn, S. D.; Gabel, R. A.; Zingaro, G. J.; Krause, S. M.; Siegl, P. K. S.; Clineschmidt, B. V.; Greenlee, W. J. The discovery of L-749,329 a Highly Potent, Orally Active Antagonist of Endothelin Receptors. Abstracts; American Chemical Society National Meeting, Washington, DC, August 21-25, 1994, American Chemical Society: Washington, DC, 1994; Medicinal Chem. No. 140.
22. Walsh, T. F. Progress in the Development of Endothelin Receptor Antagonists. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1995; Vol. 30, pp 91-100.
23. Doherty, A. M.; Patt, W. C.; Edmunds, J. J.; Berryman, K. A.; Reisdorph, B. R.; Plummer, M. S.; Shahripour, A.; Lee, C.; Cheng, X. M.; Walker, D. M.; Haleen, S.J.; Keiser, J. A.; Flynn, M. A.; Welch, K. M.; Hallak, H.; Taylor, D. G.; Reynolds, E. E. Discovery of a Novel Series of Orally Active Non-Peptide Endothelin-A Receptor Selective Antagonists. J. Med. Chem. 1995, 38, 1259-1263.
24. Clozel, M.; Breu, V.; Gray, G. A.; Kalina, B.; Loffler, B.; Burri, K.; Cassal, J.; Hirth, G.; Muller, M.; Neidhart, W.; Ramuz, H. Pharmacological Characterization of Bosentan, a New Potent Orally Active Non-peptide Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1994, 270, 228-235.
25. A receptors.
26. max, which is the total number of receptors.
27. Kamlet, M. J. The Michael Reaction in Non-alkaline Media. I. The synthesis of 5-(2-Nitro-1-arylethyl)barbituric Acids. J. Am. Chem. Soc. 1955, 77, 4896.
28. By the method of Krapcho, A. P.; Diamani, J.; Cayen, C.; Bingham, R. 2-Carbethoxy cyclooctanone. Organic Synthesis, John Wiley: New York, 1967; Vol. 47, p 20.
29. Weaver, W. E.; Whaley, W. M. Organic Fungicides. I The Preparation of Some Bromoacetamides. J Am. Chem. Soc. 1947, 69, 515.
30. Carless, H. A. J.; Batten, R. J. Photosensitized Oxidation of Model Unsaturated Lipid Systems: (4Z, 7Z)-Undeca-4,7-diene and (4Z)-Undec-4-en-7-yne. J. Chem. Soc. Perkin Trans. 1987, 1999.
31. Hoshino, O.; Saito, K.; Ishizaki, M.; Umezawa, B. A Convenient Preparation of Certain N,N-Dialkylcarbamoyl Chlorides. Synth. Commun. 1987, 17, 1887-1892.
32. Bowman, R. E. N-Substituted Amino Acids. II The Reductive Alkylation of Amino Acids. J. Chem Soc. 1950, 1346.
33. Kaldor, S. W.; Hammond, M. A Mild Osmium Tetroxide Catalyzed Method for the Oxidation of Sulfides to Sulfones. Tetrahedron Lett. 1991, 32, 5043-5046.
34. Berridge, M. J.; Downes, C. P.; Hanley, M. R Lithium Amplifies Agonist Dependent Phosphatidylinositol Responses in Brain and Salivary Glands. Biochem. J. 1982, 206, 587-595.
35. Statistical Consultants, Inc. PCNONLIN and NONLIN84: Software for the Statistical Analysis of Nonlinear Models. Am. Statistician 1986, 40, 52.
36. Sedman, A. J.; Wagner, J. G. CSTRIP-A FORTRAN Computer Program for Obtaining Initial Polyexponential Esimates. J. Pharm. Sci. 1976, 65, 1006-1010.